 |
17 Diseases |  |
0 Trials |
|
0 Trials |  |
64 News |  |
| «12 |
- |||||||||| Androxal (enclomifene) / AbbVie
New P3 trial: An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism (clinicaltrials.gov) - Nov 29, 2012
P3, N=300, Completed, Sponsor: Repros Therapeutics Inc.
- | Androxal (enclomifene) / AbbVie
Enrollment change: The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone) (clinicaltrials.gov) - Aug 30, 2012
P2, N=48, Completed, Sponsor: Repros Therapeutics Inc.
N=60 --> 48
- ||| Androxal (enclomifene) / AbbVie
Enrollment change: Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism (clinicaltrials.gov) - Aug 30, 2012
P2b, N=83, Completed, Sponsor: Repros Therapeutics Inc.
N=60 --> 48 N=120 --> 83
- ||| Androxal (enclomifene) / AbbVie
Enrollment change: Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Aug 30, 2012
P2, N=102, Completed, Sponsor: Repros Therapeutics Inc.
N=120 --> 83 N=150 --> 102
- | Androxal (enclomifene) / AbbVie
Trial completion: The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone) (clinicaltrials.gov) - Aug 30, 2012
P2, N=48, Completed, Sponsor: Repros Therapeutics Inc.
N=150 --> 102 Active, not recruiting --> Completed
- |||| Androxal (enclomifene) / AbbVie
Trial completion: Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism (clinicaltrials.gov) - Aug 30, 2012
P2b, N=83, Completed, Sponsor: Repros Therapeutics Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Androxal (enclomifene) / AbbVie
Trial completion: Study to Evaluate the Efficacy of Androxal in Controlling Blood Glucose in Men With Type-2 Diabetes Mellitus (clinicaltrials.gov) - Aug 30, 2012
P2, N=102, Completed, Sponsor: Repros Therapeutics Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Androxal (enclomifene) / AbbVie
New P3 trial: Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism (clinicaltrials.gov) - Jun 12, 2012
P3, N=300, Active, not recruiting, Sponsor: Repros Therapeutics Inc.
- ||||| Androxal (enclomifene) / AbbVie
Trial initiation date: Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism (clinicaltrials.gov) - Jun 11, 2012
P3, N=151, Completed, Sponsor: Repros Therapeutics Inc.
Active, not recruiting --> Completed Initiation date: May 2012 --> Aug 2012
- |||||||||| Androxal (enclomifene) / AbbVie
New P3 trial: Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism (clinicaltrials.gov) - Feb 14, 2012
P3, N=499, Completed, Sponsor: Repros Therapeutics Inc.
- |||||||||| Androxal (enclomifene) / AbbVie
New P3 trial: Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism (clinicaltrials.gov) - Feb 12, 2012
P3, N=151, Completed, Sponsor: Repros Therapeutics Inc.